Asia
Sungho Han, Ph.D., founder and CEO of Genuv Inc. in Seoul, South Korea, has built her career and her company by thinking outside the box.
Biopharma and life sciences organizations from across the globe provide updates on their pipelines and businesses.
Monday was a big day for LianBio, as the Shanghai-based company launched on the Nasdaq with an impressive $325 million initial public offering (IPO).
This novel diagnostic technology uses augmented reality and a smartphone or tablet to administer cognitive and functional tests.
One year after snagging $310 million in a financing round, LianBio raised $325M in its initial public offering. Its stock begins selling today on Nasdaq under the ticker symbol “LIAN.”
As the world marks a grim milestone of 5 million COVID-19 deaths, public health officials are keeping a close watch on a substrain of the Delta variant.
Daiichi Sankyo announced the decision in its third quarter financial report this morning, where it said that the Phase I data yielded no clear responses in GIST patients.
Yet another busy week for clinical trial news. Here’s a look.
The deal was struck one month after GammaDelta dosed its first patient in a Phase I acute myeloid leukemia (AML) trial.
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
PRESS RELEASES